← Back to Search

Monoclonal Antibodies

EphB4-HSA + Pembrolizumab for Cancer

Phase 2
Waitlist Available
Led By Jorge Nieva, MD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale
Patients may have received up to 2 prior lines of chemotherapy
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying a combination of a protein and an antibody to treat patients with non-small cell lung or head and neck squamous cell cancer.

Who is the study for?
This trial is for adults with certain advanced cancers, including non-small cell lung cancer and head and neck squamous cell carcinoma that have worsened despite treatment. Participants must have specific blood levels within normal ranges, be willing to provide tissue samples, not be pregnant or breastfeeding, agree to use contraception if of childbearing potential, and cannot have had certain treatments recently or suffer from severe allergies or immune conditions.Check my eligibility
What is being tested?
The study tests a combination of a recombinant EphB4-HSA fusion protein that may block tumor growth enzymes and pembrolizumab, an antibody that could prevent cancer cells from growing. It's for patients whose cancer has spread or returned after previous therapies. The goal is to see if this combo works better than current treatments.See study design
What are the potential side effects?
Possible side effects include allergic reactions to the drug components (pembrolizumab), issues related to immune system suppression such as increased risk of infections, potential liver function changes reflected in blood tests, fatigue due to anemia or other causes related directly or indirectly to the treatment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am fully active or restricted in physically strenuous activity but can do light work.
I have had up to 2 chemotherapy treatments before.
I have refused first-line platinum-based chemotherapy.
My cancer returned within 6 months after treatment with cisplatin.
I agree to use birth control during and up to 120 days after the study.
I agree to provide a tissue sample from my tumor after 2 treatment cycles.
My lung cancer has worsened after chemotherapy.
I have had up to 2 chemotherapy treatments before.
My cancer progressed despite treatment with specific targeted therapy.
I have refused first-line platinum-based chemotherapy.
My head or neck cancer got worse after platinum-based treatment.
My cancer has returned or spread to other parts of my body.
My kidney function is within the normal range or slightly above.
My blood clotting time is normal or managed with medication.
I am a man who can father a child and will use birth control during and for 4 months after the study.
My blood clotting time is normal or managed if I'm on blood thinners.
My hemoglobin level is above 9 g/dL without needing transfusions or EPO recently.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Heart rate
Secondary outcome measures
Duration of response
Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Overall survival (OS)
+1 more
Other outcome measures
Biomarker analysis of PD-1 and PD-L1 assessed by archived tumor tissue by immunohistochemical testing

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (pembrolizumab, sEphB4-HSA)Experimental Treatment3 Interventions
Patients receive pembrolizumab IV over 30 minutes on day 1 and recombinant EphB4-HSA fusion protein IV over 30 minutes on days 1, 8, and 15. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
903 Previous Clinical Trials
1,596,096 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,635 Previous Clinical Trials
40,929,531 Total Patients Enrolled
Jorge Nieva, MDPrincipal InvestigatorUniversity of Southern California
1 Previous Clinical Trials
250 Total Patients Enrolled

Media Library

Pembrolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03049618 — Phase 2
Head and Neck Squamous Cell Carcinoma Research Study Groups: Treatment (pembrolizumab, sEphB4-HSA)
Head and Neck Squamous Cell Carcinoma Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT03049618 — Phase 2
Pembrolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03049618 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What maladies has Recombinant EphB4-HSA Fusion Protein been employed to address?

"Recombinant EphB4-HSA Fusion Protein is often prescribed to treat malignant neoplasms and other medical issues, such as advanced melanoma, high microsatellite instability levels, or disease progression after chemotherapy."

Answered by AI

What potential hazards should be considered when using Recombinant EphB4-HSA Fusion Protein?

"According to our internal assessment, Recombinant EphB4-HSA Fusion Protein has been rated as a 2 on the scale of 1 to 3. This is due to this being a Phase 2 trial with some evidence supporting its safety but not yet any efficacy data."

Answered by AI

Are there still opportunities for participation in this clinical experiment?

"At this time, participation in the trial is not being accepted. The research was first posted on March 10th of 2017 and last updated November 18th 2022. For those searching for other opportunities to participate, 5068 clinical trials are recruiting patients with malignant neoplasms and 965 studies require participants who will receive Recombinant EphB4-HSA Fusion Protein treatment."

Answered by AI

Are there any historical precedents of employing Recombinant EphB4-HSA Fusion Protein in clinical trials?

"At this time, the research of Recombinant EphB4-HSA Fusion Protein has been taken on by 965 studies. Of these investigations, 122 have advanced to Phase 3 trials. Despite a concentration in Houston, Texas - 35744 other sites are conducting studies for this medicinal intervention."

Answered by AI

What is the overall participant count of this experiment?

"At this moment in time, no new candidates are being accepted for this clinical trial. Initially posted on 3/10/2017 and last edited on 11/18/2022, the study is currently dormant. If you're looking to participate in other trials related to malignant neoplasms there's 5068 studies actively enrolling participants while 965 seek people willing to try Recombinant EphB4-HSA Fusion Protein treatments."

Answered by AI
~4 spots leftby Mar 2025